{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T05:03:09Z","timestamp":1785301389909,"version":"3.55.0"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This prospective multicenter observational study, designed by the Greek Research Alliance for the Study of Headache and Pain (GRASP), evaluated the real-world effectiveness and tolerability of oral fixed-dose sumatriptan 85\u202fmg\/naproxen sodium 500\u202fmg across repeated migraine attacks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Adults with episodic or chronic migraine for whom the treating physician had selected the oral fixed-dose combination as acute treatment were enrolled. Outcomes were recorded for up to three consecutive treated migraine attacks. The primary endpoint was 2-h pain freedom. Secondary endpoints included 2-h pain relief, sustained pain freedom at 24\u202fh without rescue medication, return to normal activities, resolution of associated symptoms, treatment-timing effects, subgroup outcomes, and adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall, 111 patients contributed 320 treated attacks. Two-hour pain freedom was achieved in 76\/320 attacks (23.8%; 95%CI: 19.4\u201328.7), 2-h pain relief in 220\/320 attacks (68.8%; 95%CI: 63.5\u201373.6), full return to normal activities in 206\/320 attacks (64.4%; 95%CI: 59.0\u201369.4), and no rescue medication use in 246\/320 attacks (76.9%; 95%CI: 72.0\u201381.2). Associated symptoms improved substantially, with 2-h resolution of photophobia, phonophobia, and nausea\/vomiting occurring in 49.0, 51.0, and 63.7% of affected attacks, respectively. Early treatment within 1 h was associated with higher pain relief and functional recovery. Adverse events, occurring in 20.0% of attacks, were mainly gastrointestinal symptoms, dizziness, chest pressure, and somnolence\/fatigue.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Fixed-dose sumatriptan\/naproxen sodium was associated with modest 2-h pain freedom but clinically meaningful pain relief, functional recovery, and low rescue medication use. Tolerability was consistent with the known profiles of triptans and non-steroidal anti-inflammatory drugs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fneur.2026.1912200","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T04:41:25Z","timestamp":1785300085000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness and safety of sumatriptan 85 mg\/naproxen sodium 500 mg combination for acute migraine: prospective real-world evidence from the GRASP Study Group"],"prefix":"10.3389","volume":"17","author":[{"given":"Dimitrios","family":"Rikos","sequence":"first","affiliation":[{"name":"404 Military Hospital","place":["Larisa, Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas A.","family":"Argyriou","sequence":"additional","affiliation":[{"name":"Department of Neurology, Headache Outpatient Clinic, Agios Andreas General Hospital of Patras","place":["Patras, Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanouil V.","family":"Dermitzakis","sequence":"additional","affiliation":[{"name":"General Clinic","place":["Thessaloniki, Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis","family":"Soldatos","sequence":"additional","affiliation":[{"name":"Kalamata Headache Clinic","place":["Kalamata, Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Dimisianos","sequence":"additional","affiliation":[{"name":"General Neurology Clinic","place":["Corfu, Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Tsironis","sequence":"additional","affiliation":[{"name":"Department of Neurology, Headache Outpatient Clinic, University Hospital of Ioannina","place":["Ioannina, Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Mavraki","sequence":"additional","affiliation":[{"name":"Department of Neurology, Headache Outpatient Clinic, University General Hospital of Alexandroupolis","place":["Alexandroupolis, Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Chondrogianni","sequence":"additional","affiliation":[{"name":"Second Department of Neurology, National and Kapodistrian University of Athens, School of Medicine, \u201cAttikon\u201d University Hospital","place":["Athens, Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aikaterini","family":"Foska","sequence":"additional","affiliation":[{"name":"Second Department of Neurology, National and Kapodistrian University of Athens, School of Medicine, \u201cAttikon\u201d University Hospital","place":["Athens, Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelia","family":"Dimitriadou","sequence":"additional","affiliation":[{"name":"Second Department of Neurology, National and Kapodistrian University of Athens, School of Medicine, \u201cAttikon\u201d University Hospital","place":["Athens, Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanouil","family":"Giakoumakis","sequence":"additional","affiliation":[{"name":"NeuroCrete Headache Clinic","place":["Heraklion, Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michail","family":"Vikelis","sequence":"additional","affiliation":[{"name":"Glyfada Headache Clinic","place":["Glyfada, Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of Greek Research Alliance for the Study of Headache and Pain (GRASP) Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,29]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/S1474-4422(24)00038-3","article-title":"Global, regional, and national burden of disorders affecting the nervous system, 1990-2021: a systematic analysis for the global burden of disease study 2021","volume":"23","year":"2024","journal-title":"Lancet Neurol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"102348","DOI":"10.1016\/j.xcrm.2025.102348","article-title":"Global, regional, and national burden of headache disorders, 1990-2021, with forecasts to 2050: a global burden of disease study 2021","volume":"6","year":"2025","journal-title":"Cell Rep Med"},{"key":"ref3","first-page":"3331024241252666","article-title":"International headache society global practice recommendations for the acute pharmacological treatment of migraine","volume-title":"Cephalalgia","author":"Puledda","year":"2024"},{"key":"ref4","first-page":"3331024241305381","article-title":"Evidence-based guidelines for the pharmacological treatment of migraine","volume-title":"Cephalalgia","author":"Ornello","year":"2025"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1111\/head.14245","article-title":"The American headache society consensus statement: update on integrating new migraine treatments into clinical practice","volume":"62","author":"Burch","year":"2022","journal-title":"Headache"},{"key":"ref6","first-page":"e080107","article-title":"Comparative effects of drug interventions for the acute management of migraine episodes in adults: systematic review and network meta-analysis","volume-title":"BMJ","author":"Karlsson","year":"2024"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"e16434","DOI":"10.1111\/ene.16434","article-title":"Sumatriptan-naproxen sodium in migraine: A review","volume":"31","author":"Wilcha","year":"2024","journal-title":"Eur J Neurol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s40265-015-0521-8","article-title":"Sumatriptan\/naproxen sodium: a review in migraine","volume":"76","author":"Syed","year":"2016","journal-title":"Drugs"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1007\/s40265-013-0099-y","article-title":"Sumatriptan\/naproxen sodium: a review of its use in adult patients with migraine","volume":"73","author":"Yang","year":"2013","journal-title":"Drugs"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2147\/DDDT.S8410","article-title":"Sumatriptan-naproxen fixed combination for acute treatment of migraine: a critical appraisal","volume":"4","author":"Khoury","year":"2010","journal-title":"Drug Des Devel Ther"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1001\/jama.297.13.1443","article-title":"Sumatriptan-naproxen for acute treatment of migraine: a randomized trial","volume":"297","author":"Brandes","year":"2007","journal-title":"JAMA"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1111\/j.1526-4610.2005.05178.x","article-title":"Sumatriptan and naproxen sodium for the acute treatment of migraine","volume":"45","author":"Smith","year":"2005","journal-title":"Headache"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1212\/01.wnl.0000316800.22949.20","article-title":"Multimechanistic (sumatriptan-naproxen) early intervention for the acute treatment of migraine","volume":"71","author":"Silberstein","year":"2008","journal-title":"Neurology"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1177\/0333102413508242","article-title":"Sumatriptan\/naproxen sodium for the acute treatment of probable migraine without aura: a randomized study","volume":"34","author":"Silberstein","year":"2014","journal-title":"Cephalalgia"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1097\/AOG.0b013e3181a98e4d","article-title":"Combination treatment for menstrual migraine and dysmenorrhea using sumatriptan-naproxen: two randomized controlled trials","volume":"114","author":"Mannix","year":"2009","journal-title":"Obstet Gynecol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1111\/j.1526-4610.2011.01894.x","article-title":"Sumatriptan-naproxen sodium for menstrual migraine and dysmenorrhea: satisfaction, productivity, and functional disability outcomes","volume":"51","author":"Cady","year":"2011","journal-title":"Headache"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3810\/pgm.2014.03.2743","article-title":"Double-blind, placebo-controlled, crossover study of early-intervention with sumatriptan 85\/naproxen sodium 500 in (truly) episodic migraine: what's neck pain got to do with it?","volume":"126","author":"Calhoun","year":"2014","journal-title":"Postgrad Med"},{"key":"ref18","first-page":"53","article-title":"Two double-blind, multicenter, randomized, placebo-controlled, single-dose studies of sumatriptan\/naproxen sodium in the acute treatment of migraine: function, productivity, and satisfaction outcomes","volume":"9","author":"Landy","year":"2007","journal-title":"MedGenMed"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1111\/j.1751-7176.2011.00554.x","article-title":"Evaluation of the migraine treatment sumatriptan\/naproxen sodium on blood pressure following long-term administration","volume":"13","author":"White","year":"2011","journal-title":"J Clin Hypertens"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/0333102417738202","article-title":"The international classification of headache disorders, 3rd edition","volume":"38","year":"2018","journal-title":"Cephalalgia"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1177\/0333102419828967","article-title":"Guidelines of the international headache society for controlled trials of acute treatment of migraine attacks in adults: fourth edition","volume":"39","author":"Diener","year":"2019","journal-title":"Cephalalgia"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1046\/j.1526-4610.2002.0420s1003.x","article-title":"What do patients with migraine want from acute migraine treatment?","volume":"42","author":"Lipton","year":"2002","journal-title":"Headache"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1111\/head.14067","article-title":"Systematic review of outcomes and endpoints in acute migraine clinical trials","volume":"61","author":"Houts","year":"2021","journal-title":"Headache"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"CD008541","DOI":"10.1002\/14651858.cd008541.pub3","article-title":"Sumatriptan plus naproxen for the treatment of acute migraine attacks in adults","volume":"4","author":"Law","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1111\/j.1526-4610.2007.00790.x","article-title":"Sumatriptan\/naproxen sodium for migraine: efficacy, health related quality of life, and satisfaction outcomes","volume":"47","author":"Smith","year":"2007","journal-title":"Headache"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/j.1468-2982.2008.01688.x","article-title":"Early treatment in migraine: how strong is the current evidence?","volume":"28","author":"Gendolla","year":"2008","journal-title":"Cephalalgia"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1007\/s13311-017-0592-1","article-title":"Migraine treatment: current acute medications and their potential mechanisms of action","volume":"15","author":"Ong","year":"2018","journal-title":"Neurotherapeutics"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1177\/0333102410381145","article-title":"Disability, HRQoL and resource use among chronic and episodic migraineurs: results from the international burden of migraine study (IBMS)","volume":"31","author":"Blumenfeld","year":"2011","journal-title":"Cephalalgia"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1111\/head.13966","article-title":"Demographics, headache features, and comorbidity profiles in relation to headache frequency in people with migraine: results of the American migraine prevalence and prevention (AMPP) study","volume":"60","author":"Buse","year":"2020","journal-title":"Headache"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s10194-022-01502-z","article-title":"European headache federation (EHF) consensus on the definition of effective treatment of a migraine attack and of triptan failure","volume":"23","author":"Sacco","year":"2022","journal-title":"J Headache Pain"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1912200\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T04:41:40Z","timestamp":1785300100000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1912200\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,29]]},"references-count":30,"alternative-id":["10.3389\/fneur.2026.1912200"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2026.1912200","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,29]]},"article-number":"1912200"}}